A Randomized, Double-blind, Vehicle-controlled, Parallel Group, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Dose TDM-105795 Topical Solution in Healthy Male Subjects With AGA
Latest Information Update: 28 Apr 2022
At a glance
- Drugs TDM-105795 (Primary)
- Indications Alopecia
- Focus Adverse reactions
- Sponsors TechnoDerma Medicines
- 26 Apr 2022 Status changed from recruiting to completed.
- 10 Jun 2021 New trial record